{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:47:19Z","timestamp":1786992439406,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","geriatriconcology.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jgo.2024.102153","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:36:03Z","timestamp":1731465363000},"page":"102153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["\u201cStart low, go slow,\u201d a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"16","author":[{"given":"Gabriel","family":"Aleixo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will J.","family":"Ferrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efrat","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel U.","family":"Takvorian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi B.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Sedhom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2024.102153_bb0005","author":"NCI"},{"issue":"1","key":"10.1016\/j.jgo.2024.102153_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2022.10.008","article-title":"Predicting future cancer incidence by age, race, ethnicity, and sex","volume":"14","author":"Garner","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2024.102153_bb0015","first-page":"61","article-title":"Frailty: a common pathway in aging and cancer","volume":"38","author":"Balducci","year":"2013","journal-title":"Interdiscip Top Gerontol"},{"issue":"2","key":"10.1016\/j.jgo.2024.102153_bb0020","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.pec.2010.04.032","article-title":"Health outcome prioritization to elicit preferences of older persons with multiple health conditions","volume":"83","author":"Fried","year":"2011","journal-title":"Patient Educ Couns"},{"issue":"20","key":"10.1016\/j.jgo.2024.102153_bb0025","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/archinternmed.2011.424","article-title":"Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions","volume":"171","author":"Fried","year":"2011","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1016\/j.jgo.2024.102153_bb0030","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1634\/theoncologist.2019-0166","article-title":"Inclusion of older patients with cancer in clinical trials: the SAGE prospective multicenter cohort survey","volume":"24","author":"Canoui-Poitrine","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jgo.2024.102153_bb0035","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jgo.2017.02.010","article-title":"Functional decline in older patients with cancer receiving chemotherapy: a multicenter prospective study","volume":"8","author":"Kenis","year":"2017","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2024.102153_bb0040","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/jamaoncol.2015.0891","article-title":"Improving patient safety in clinical oncology: applying lessons from normal accident theory","volume":"1","author":"Chera","year":"2015","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2024.102153_bb0045","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/14740338.2020.1805429","article-title":"Is the lack of evidence in older adults with cancer compromising safety?","volume":"19","author":"Outlaw","year":"2020","journal-title":"Expert Opin Drug Saf"},{"issue":"9779","key":"10.1016\/j.jgo.2024.102153_bb0050","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(11)60399-1","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour","year":"2011","journal-title":"Lancet"},{"issue":"7414","key":"10.1016\/j.jgo.2024.102153_bb0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jgo.2024.102153_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jclinepi.2017.07.008","article-title":"Heterogeneity in application, design, and analysis characteristics was found for controlled before-after and interrupted time series studies included in Cochrane reviews","volume":"91","author":"Polus","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jgo.2024.102153_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.jgo.2024.102153_bb0070","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/ggi.14243","article-title":"Efficacy of erlotinib and its effects on the quality of life of older patients with epidermal growth factor receptor-mutant non-small cell lung cancer: a prospective, multicenter, dose-modification study","volume":"21","author":"Tsubata","year":"2021","journal-title":"Geriatr Gerontol Int"},{"issue":"24","key":"10.1016\/j.jgo.2024.102153_bb0075","doi-asserted-by":"crossref","first-page":"22038","DOI":"10.1002\/cam4.6786","article-title":"Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: a single-arm, multicenter, phase II study","volume":"12","author":"Tan","year":"2023","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.jgo.2024.102153_bb0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11523-019-00642-8","article-title":"Comparison of standard initial dose and reduced initial dose regorafenib for colorectal cancer patients: a retrospective cohort study","volume":"14","author":"Nakashima","year":"2019","journal-title":"Target Oncol"},{"issue":"16","key":"10.1016\/j.jgo.2024.102153_bb0085","article-title":"Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial","volume":"41","author":"Badri","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"7","key":"10.1016\/j.jgo.2024.102153_bb0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.1250","article-title":"Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation-positive non-small cell lung cancer: a multicenter phase 2 trial","volume":"6","author":"Miyamoto","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.jgo.2024.102153_bb0095","doi-asserted-by":"crossref","first-page":"233 e15","DOI":"10.1016\/j.urolonc.2020.09.013","article-title":"Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer","volume":"39","author":"Miura","year":"2021","journal-title":"Urol Oncol"},{"issue":"1101","key":"10.1016\/j.jgo.2024.102153_bb0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/postgradmedj-2016-134547","article-title":"The real-world use of regorafenib for metastatic colorectal cancer: multicentre analysis of treatment pattern and outcomes in Hong Kong","volume":"93","author":"Lam","year":"2017","journal-title":"Postgrad Med J"},{"issue":"4","key":"10.1016\/j.jgo.2024.102153_bb0105","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s10147-012-0443-3","article-title":"Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients","volume":"18","author":"Kita","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jgo.2024.102153_bb0110","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2024.102153_bb0115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000336082","article-title":"Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma","volume":"82","author":"Kim","year":"2012","journal-title":"Oncology"},{"issue":"31","key":"10.1016\/j.jgo.2024.102153_bb0120","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study","volume":"35","author":"Reiss","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2024.102153_bb0125","series-title":"Impact of dose adjustment on clinical outcome of levantinib treated patients with advanced hepatocellular carcinoma presented at: international liver cancer association 16th annual conference","author":"Chan","year":"2022"},{"issue":"10314","key":"10.1016\/j.jgo.2024.102153_bb0130","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/S0140-6736(21)01789-X","article-title":"Evaluation of geriatric assessment and management on the toxic effects of cancer treatment (GAP70+): a cluster-randomised study","volume":"398","author":"Mohile","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jgo.2024.102153_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2022.08.012","article-title":"Chemotherapy dosing in older adults with cancer: one size does NOT fit all","volume":"14","author":"Williams","year":"2023","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"10.1016\/j.jgo.2024.102153_bb0140","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1001\/jamaoncol.2022.5020","article-title":"Clinical trial participation among older adult medicare fee-for-service beneficiaries with cancer","volume":"8","author":"Green","year":"2022","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2024.102153_bb0145","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jamaoncol.2021.0848","article-title":"Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer: the GO2 phase 3 randomized clinical trial","volume":"7","author":"Hall","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2024.102153_bb0150","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1200\/OP.22.00427","article-title":"Oncologists\u2019 perspectives on individualizing dose selection for patients with metastatic cancer","volume":"18","author":"Jimenez","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jgo.2024.102153_bb0155","author":"ASCO"},{"key":"10.1016\/j.jgo.2024.102153_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/OP.23.00539","article-title":"The right dose: results of a patient advocate-led survey of individuals with metastatic breast cancer regarding treatment-related side effects and views about dosage assessment to optimize quality of life","author":"Loeser","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jgo.2024.102153_bb0165","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/164_2019_302","article-title":"The future of clinical trial design: the transition from hard endpoints to value-based endpoints","volume":"260","author":"Kruizinga","year":"2019","journal-title":"Handb Exp Pharmacol"},{"issue":"15","key":"10.1016\/j.jgo.2024.102153_bb0170","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1158\/1078-0432.CCR-05-0458","article-title":"New paradigm in dose-finding trials: patient-specific dosing and beyond phase I","volume":"11","author":"Rogatko","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.jgo.2024.102153_bb0175","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology - when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jgo.2024.102153_bb0180","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.anclin.2015.05.004","article-title":"Geriatric pharmacology","volume":"33","author":"Akhtar","year":"2015","journal-title":"Anesthesiol Clin"},{"issue":"3","key":"10.1016\/j.jgo.2024.102153_bb0185","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.emc.2016.04.003","article-title":"Pharmacology in the geriatric patient","volume":"34","author":"Welker","year":"2016","journal-title":"Emerg Med Clin North Am"},{"issue":"10","key":"10.1016\/j.jgo.2024.102153_bb0190","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/annonc\/mdu052","article-title":"Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review","volume":"25","author":"Versteeg","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2024.102153_bb0195","article-title":"Dosing schedules of gemcitabine and nab-paclitaxel for older adults with metastatic pancreatic cancer","volume":"5","author":"Winer","year":"2021","journal-title":"JNCI Cancer Spectr"},{"issue":"4","key":"10.1016\/j.jgo.2024.102153_bb0200","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jgo.2016.02.007","article-title":"Geriatric assessment with management in cancer care: current evidence and potential mechanisms for future research","volume":"7","author":"Magnuson","year":"2016","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2024.102153_bb0205","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jgo.2018.03.001","article-title":"Geriatric oncology screening tools for CGA-based interventions: results from a phase II study of geriatric assessment and management for older adults with cancer","volume":"9","author":"Yokom","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"20","key":"10.1016\/j.jgo.2024.102153_bb0210","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1200\/JCO.2015.65.4327","article-title":"Validation of a prediction tool for chemotherapy toxicity in older adults with cancer","volume":"34","author":"Hurria","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824004260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406824004260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:51:45Z","timestamp":1741132305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406824004260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1879406824004260"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2024.102153","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cStart low, go slow,\u201d a strategy to tailor treatment dosing in older or vulnerable adults with advanced solid cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2024.102153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102153"}}